Please login to the form below

Not currently logged in
Email:
Password:

Bayer expands research deal with university in China

Collaboration with Tsinghua University extended by three years, with Bayer to fund chair of Institute of Biomedicine

Bayer Healthcare has expanded a deal with Tsinghua University of Beijing, China, to research innovative medicines until 2015.

The deal extends an existing partnership, established in 2009, which has led to multiple joint research projects as part of the Bayer-Tsinghua Joint Research Center for Innovative Drug Discovery(BTC).

“The decision to further develop this successful research collaboration underlines Bayer's commitment to China as an important component of our innovation strategy,” said Professor Andreas Busch, head of global drug discovery at Bayer.

As part of the expanded partnership, research will widen to include structural biology, with Tsinghua students to work with Bayer scientists to investigate the 3D protein structure of biological molecules identified as drug targets.

Bayer will also install Dr Dong Chen as the company's first endowed chair at Tsinghua's Institute of Biomedicine.

“The establishment serves as another example for Bayer´s commitment to support world class research achievements,” said Dr Jennifer Hu, head of global drug discovery at Bayer Healthcare's innovation centre in China.

Further academic collaborations exist with Tongji University where Bayer funds the university's chair for sustainable development, and the China-Europe International Business School, where the company endows the chair for marketing and strategy.

Other ongoing research partnerships between Bayer and China include an agreement with the Chinese Academy of Sciences, which aims to improve academic exchange in R&D and to improve mutual access to research facilities.

German-based Bayer has also spoken of its intent to improve sales in China, in addition to expanding its R&D efforts.

In November 2011, the group outlined targets for its Asia business that include increasing its revenues in China by 60 per cent to €11bn within the next four years.

28th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Blog_icon_why-pull-beats-push-in-digital-sales-communication-300x200.png
Two ‘must haves’ for multichannel success
What do great multichannel projects have in common? At a recent Anthill webinar, speakers highlighted two essentials for multichannel success....
BrAInPME.png
The future of medical content: The personal touch
The purpose of delivering personalised content to HCPs is not just about customer experience, it's about improving healthcare. Our Commercial Director, Tib Catania discusses what ‘deep learning’ means for the...
Rise of the patient expert - an interview with Michael Seres
Founded by Michael Seres in 2011, 11 Health is a connected medical device company currently working to change the lives of patients using stoma bags. Content Marketing Manager Liz Inskip...

Infographics